20 Investments in associates and joint ventures Joint 2013 Joint 2012 ventures Associates Total ventures Associates Total m m m m m m At 1 January 22 557 579 29 531 560 Exchange adjustments 3 109 112 3 32 35 Additions 1 7 8 58 41 99 Disposals 1 139 140 Transfer to other investments 37 37 2 16 18 25 21 46 Distributions received 7 21 28 Other movements Loss profit after tax recognised in the consolidated 2 45 43 30 59 29 income statement 15 308 323 22 557 579 At 31 December Investments in joint ventures principally arise from a 50% interest in one joint venture, Japan Vaccine Co. Ltd. with Daiichi Sankyo Co. Ltd.
The joint venture holds the development and commercial rights for existing preventative vaccines from both parent companies.
It will supply vaccines including Human Papillomavirus HPV vaccine, Rotavirus vaccine, Seasonal flu vaccine, Mumps vaccine, Diphtheria Pertussis DTP vaccine and Measles Rubella vaccine MRV in Japan.
The Group held one significant associate at 31 December 2013, Aspen Pharmacare Holdings Limited.
At 31 December 2013, the Group owned 56.5 million shares or 12.4% of Aspen.
Aspen, listed on the Johannesburg Stock Exchange, is Africas largest pharmaceutical manufacturer and a major supplier of branded and generic pharmaceutical, healthcare and nutritional products to the southern African and selected international markets.
The investment had a market value of 872 million 2012 1,037 million.
Although the Group holds less than 20% of the ownership interest and voting control of Aspen, the Group has the ability to exercise significant influence through both its shareholding and its nominated directors active participation on the Aspen Board of Directors.
During the year the Group disposed of 6.2% of its shareholding see Note 35.
Summarised balance sheet information in respect of Aspen is set out below: 2013 2012 m m Non-current assets 1,442 1,268 Current assets 968 789 Current liabilities 869 564 Non-current liabilities 672 520 Net assets 869 973 The summarised balance sheet information in respect of Aspen is based on preliminary results information and analysts forecasts available at 31 December 2013 with adjustments for transactions between GSK and Aspen.
A reconciliation of the summarised financial information to the carrying amount of the Aspen investment is set out below: 2013 2012 m m At 1 January 973 797 Profit for the year 247 313 Other comprehensive income 192 163 Exchange adjustments 289 39 Dividends paid 45 54 Other movements 209 285 At 31 December 869 973 Interest in associated undertaking at 12.4% 2012 18.6% 108 181 Goodwill 121 249 Carrying value at 31 December 229 430 GSK Annual Report 2013 161
